Alvotech (ALVO) Q3 2026 Earnings Call Transcript
Alvotech (ALVO) reported Q3 2026 earnings, highlighting FDA approvals, strong revenue growth, and strategic partnerships. Revenue for the first 9 months was $323 million, with EBITDA of $78 million, up 15% year-over-year. The company expects Q4 to be its strongest quarter and anticipates performance to trend towards the lower end of its stated range.
How this was made

The 30-second read
Why it matters
Earnings release provides fresh financial data and a lowered outlook, influencing investor sentiment and price.
Market read
First earnings disclosure for Q3 2026 with guidance cut, material for traders in biotech space.
What to watch
Recent FDA approvals and expanded manufacturing capacity may offset short‑term guidance concerns.
Background
Alvotech discussed Q3 results, manufacturing expansions, new US partnership with Lotus, and regulatory milestones.
Ticker impact
Q3 revenue $323M, EBITDA $78M (+15% YoY) and guidance lowered to the lower end of the previously stated range.
downside pressure as market prices in the lower guidance
Guidance reduction is a material new fact that typically triggers a sell-off in biotech stocks.
Market effects
Biotech sector may see modest pullback as guidance cuts raise concerns on pipeline timing.
European biotech investors could reassess exposure to biosimilar developers.
Limited to niche biosimilar market; no broad macro impact.
Counterpoint
Despite guidance cut, strong pipeline and new US partnership could drive upside if execution succeeds.
Key entities
- companyAlvotech
Biopharma developing biosimilars, ticker ALVO.
- partnerLotus Pharmaceutical
Strategic partner for US commercialization of biosimilars.


